Literature DB >> 28118147

Evaluation of NT-proBNP in children with heart failure younger than 3 years old.

Daniela Iacob1, Angela Butnariu1, Daniel-Corneliu Leucuţa2, Gabriel Samaşca3, Diana Deleanu3, Iulia Lupan4.   

Abstract

INTRODUCTION: Heart failure (HF) is characterized by neuroendocrine activation. The cardiac natriuretic hormones, including atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), together with their related pro-peptides (proANP and proBNP) represent a group of peptide hormones produced by the heart. A normal NT-proBNP level has a high negative predictive value for heart failure. The use of NT-proBNP testing is helpful in diagnosing acute HF in the emergency care setting, allowing an early and optimal treatment. The purpose of this study is to assess the prognostic value of NT-proBNP in heart failure in children younger than 3 years old and to establish whether it correlates with the NYHA/Ross functional class and left ventricle systolic function.
METHODS: We enrolled 24 consecutive children with HF due to congenital heart diseases and dilated cardiomyopathy. The serum levels of NT-proBNP were measured, all patients underwent echocardiography and left ventricle ejection fraction was calculated.
RESULTS: The highest median value of NT-proBNP was recorded in patients with cyanotic heart diseases (248.0 fmol/mL), p = 0.610. NT-proBNP had a negative correlation with the ejection fraction of the left ventricle: Spearman's rank correlation coefficient was -0.165.
CONCLUSIONS: NT-proBNP levels correlate with the severity of HF in infants and small children younger than 3 years old with heart failure due to congenital heart diseases and dilated cardiomyopathy.

Entities:  

Keywords:  NT-proBNP; congenital heart diseases; dilated cardiomyopathy; left ventricle ejection fraction; serum levels

Mesh:

Substances:

Year:  2017        PMID: 28118147     DOI: 10.1515/rjim-2017-0002

Source DB:  PubMed          Journal:  Rom J Intern Med        ISSN: 1220-4749


  4 in total

1.  Prognostic value of biomarkers after cardiopulmonary bypass in pediatrics: The prospective PANCAP study.

Authors:  Sara Bobillo-Perez; Iolanda Jordan; Patricia Corniero; Monica Balaguer; Anna Sole-Ribalta; Maria Esther Esteban; Elisabeth Esteban; Francisco Jose Cambra
Journal:  PLoS One       Date:  2019-06-17       Impact factor: 3.240

2.  Expression of serum microRNA-155 and its clinical importance in patients with heart failure after myocardial infarction.

Authors:  Baojian Zhang; Biao Li; Fen Qin; Fan Bai; Chao Sun; Qiming Liu
Journal:  J Int Med Res       Date:  2019-11-10       Impact factor: 1.671

3.  Can NT-proBNP Levels Be an Early Biomarker of Reduced Left Ventricular Ejection Fraction in Preterm Infants?

Authors:  Ya-Lan Lin; Yi-Li Hung; Chung-Min Shen; Yung-Chuan Chen; Wu-Shiun Hsieh
Journal:  Children (Basel)       Date:  2022-07-03

4.  Analysis of Therapeutic Effect of Elderly Patients with Severe Heart Failure Based on LSTM Neural Model.

Authors:  Shunhong Chen; Shoudu He
Journal:  Comput Intell Neurosci       Date:  2022-08-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.